PMC:7600245 / 23194-23589 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T84","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"T85","span":{"begin":279,"end":287},"obj":"Disease"},{"id":"T86","span":{"begin":290,"end":299},"obj":"Disease"}],"attributes":[{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Importantly, a recent nonrandomized, open-label study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had significantly better therapeutic effects on SARS-CoV-2 infection, in terms of disease progression and viral clearance, than lopinavir/ritonavir with INF-α [73]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T219","span":{"begin":13,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T220","span":{"begin":42,"end":47},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Importantly, a recent nonrandomized, open-label study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had significantly better therapeutic effects on SARS-CoV-2 infection, in terms of disease progression and viral clearance, than lopinavir/ritonavir with INF-α [73]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T318","span":{"begin":42,"end":47},"obj":"Chemical"},{"id":"T319","span":{"begin":112,"end":123},"obj":"Chemical"},{"id":"T320","span":{"begin":225,"end":228},"obj":"Chemical"},{"id":"T321","span":{"begin":359,"end":378},"obj":"Chemical"},{"id":"T322","span":{"begin":359,"end":368},"obj":"Chemical"},{"id":"T323","span":{"begin":369,"end":378},"obj":"Chemical"},{"id":"T324","span":{"begin":384,"end":387},"obj":"Chemical"}],"attributes":[{"id":"A318","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A321","pred":"chebi_id","subj":"T321","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A322","pred":"chebi_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A323","pred":"chebi_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A324","pred":"chebi_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"}],"text":"Importantly, a recent nonrandomized, open-label study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had significantly better therapeutic effects on SARS-CoV-2 infection, in terms of disease progression and viral clearance, than lopinavir/ritonavir with INF-α [73]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T172","span":{"begin":0,"end":395},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Importantly, a recent nonrandomized, open-label study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had significantly better therapeutic effects on SARS-CoV-2 infection, in terms of disease progression and viral clearance, than lopinavir/ritonavir with INF-α [73]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"638","span":{"begin":225,"end":230},"obj":"Gene"},{"id":"639","span":{"begin":384,"end":389},"obj":"Gene"},{"id":"642","span":{"begin":57,"end":65},"obj":"Species"},{"id":"651","span":{"begin":112,"end":123},"obj":"Chemical"},{"id":"652","span":{"begin":359,"end":378},"obj":"Chemical"},{"id":"661","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"662","span":{"begin":284,"end":299},"obj":"Disease"}],"attributes":[{"id":"A638","pred":"tao:has_database_id","subj":"638","obj":"Gene:3451"},{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"Gene:3451"},{"id":"A642","pred":"tao:has_database_id","subj":"642","obj":"Tax:9606"},{"id":"A651","pred":"tao:has_database_id","subj":"651","obj":"MESH:C462182"},{"id":"A652","pred":"tao:has_database_id","subj":"652","obj":"MESH:C558899"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"MESH:C000657245"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Importantly, a recent nonrandomized, open-label study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had significantly better therapeutic effects on SARS-CoV-2 infection, in terms of disease progression and viral clearance, than lopinavir/ritonavir with INF-α [73]."}